Sign inJoin waitlistJoin the waitlist

Roxana Dronca

Maximizing Anti-PD-1 Therapy By Monitoring T Cell Responses In Melanoma, Lung And Other Cancer Types · Mayo Clinic College of Medicine and Science

Credentials: · · · · · ·

History

Maximizing Anti-PD-1 Therapy By Monitoring T Cell Responses In Melanoma, Lung And Other Cancer Types · Mayo Clinic College of Medicine and Science
Present
Mayo Clinic Comprehensive Cancer Center · Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
2001–2004
Internal Medicine
Corewell Health William Beaumont University Hospital
1998–2001
Transitional Resident Iuliu Hatieganu University of Medicine and Pharmacy
1997–1998
Iuliu Hațieganu University of Medicine and Pharmacy
1993–1997

Research

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
New England Journal of Medicine · 2013 · 2,799 citations
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
The Lancet · 2014 · 1,497 citations
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
JAMA · 2016 · 876 citations

Svetomir Markovic
36 papers
Lisa Kottschade
22 papers
Haidong Dong
21 papers
Aaron Mansfield
16 papers · 2 as a fellow
Robert McWilliams
15 papers
Matthew Block
14 papers · 1 as a fellow
RJ
Richard Joseph
12 papers
Sean Park
11 papers
Adil Daud
10 papers
Omid Hamid
10 papers
Stephen Hodi
10 papers
Tara Mitchell
10 papers

Grants

Role of Bim and Soluble B7-H1 in Monitoring T Cell Responses to Anti-PD-1 Therapy in Melanoma
National Cancer Institute · R21
PI · $373.7K · Mayo Clinic Rochester
2015–2017

Clinical trials

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Principal investigator · Recruiting · Phase 2
Mayo Clinic
2025–2026
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
Principal investigator · Recruiting · Phase 2
Mayo Clinic
2025–2028
Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)
Principal investigator · Completed
Mayo Clinic
2024–2025
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Principal investigator · Recruiting · Phase 2
Mayo Clinic
2024–2026